nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—TYK2—multiple sclerosis	0.564	1	CbGaD
Ruxolitinib—Tuberculosis—Dexamethasone—multiple sclerosis	0.00311	0.0346	CcSEcCtD
Ruxolitinib—Tuberculosis—Betamethasone—multiple sclerosis	0.00311	0.0346	CcSEcCtD
Ruxolitinib—Herpes zoster—Fingolimod—multiple sclerosis	0.00296	0.0329	CcSEcCtD
Ruxolitinib—Tuberculosis—Prednisone—multiple sclerosis	0.00271	0.0301	CcSEcCtD
Ruxolitinib—Myelosuppression—Cladribine—multiple sclerosis	0.00269	0.0299	CcSEcCtD
Ruxolitinib—GRK7—retina—multiple sclerosis	0.00252	0.02	CbGeAlD
Ruxolitinib—Myelosuppression—Azathioprine—multiple sclerosis	0.00219	0.0243	CcSEcCtD
Ruxolitinib—Haemorrhage intracranial—Mitoxantrone—multiple sclerosis	0.00202	0.0225	CcSEcCtD
Ruxolitinib—CAMK2G—nerve—multiple sclerosis	0.00198	0.0158	CbGeAlD
Ruxolitinib—MAP3K3—peripheral nervous system—multiple sclerosis	0.00197	0.0157	CbGeAlD
Ruxolitinib—LRRK2—nerve—multiple sclerosis	0.00196	0.0156	CbGeAlD
Ruxolitinib—GRK1—retina—multiple sclerosis	0.00182	0.0145	CbGeAlD
Ruxolitinib—RPS6KA6—brainstem—multiple sclerosis	0.00177	0.0141	CbGeAlD
Ruxolitinib—Myelosuppression—Mitoxantrone—multiple sclerosis	0.00177	0.0197	CcSEcCtD
Ruxolitinib—Herpes zoster—Cladribine—multiple sclerosis	0.00168	0.0186	CcSEcCtD
Ruxolitinib—Contusion—Cladribine—multiple sclerosis	0.00145	0.0161	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Fingolimod—multiple sclerosis	0.00143	0.0158	CcSEcCtD
Ruxolitinib—Herpes zoster—Azathioprine—multiple sclerosis	0.00136	0.0151	CcSEcCtD
Ruxolitinib—Bone pain—Cladribine—multiple sclerosis	0.00132	0.0146	CcSEcCtD
Ruxolitinib—Weight decreased—Fingolimod—multiple sclerosis	0.00126	0.014	CcSEcCtD
Ruxolitinib—ANKK1—nervous system—multiple sclerosis	0.00125	0.00995	CbGeAlD
Ruxolitinib—Infestation—Fingolimod—multiple sclerosis	0.00125	0.0138	CcSEcCtD
Ruxolitinib—Infestation NOS—Fingolimod—multiple sclerosis	0.00125	0.0138	CcSEcCtD
Ruxolitinib—PHKG2—brainstem—multiple sclerosis	0.0011	0.00877	CbGeAlD
Ruxolitinib—CAMK1D—retina—multiple sclerosis	0.00107	0.00851	CbGeAlD
Ruxolitinib—HIPK2—brainstem—multiple sclerosis	0.00106	0.00844	CbGeAlD
Ruxolitinib—PRKG2—nervous system—multiple sclerosis	0.00104	0.00824	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—multiple sclerosis	0.000997	0.00794	CbGeAlD
Ruxolitinib—GRK1—nervous system—multiple sclerosis	0.000988	0.00787	CbGeAlD
Ruxolitinib—PRKCE—nervous system—multiple sclerosis	0.000966	0.0077	CbGeAlD
Ruxolitinib—CAMK1—medulla oblongata—multiple sclerosis	0.000965	0.00768	CbGeAlD
Ruxolitinib—PLK1—Trifluridine—Cladribine—multiple sclerosis	0.000964	0.232	CbGdCrCtD
Ruxolitinib—DYRK1A—brainstem—multiple sclerosis	0.000953	0.00759	CbGeAlD
Ruxolitinib—Contusion—Mitoxantrone—multiple sclerosis	0.000952	0.0106	CcSEcCtD
Ruxolitinib—GRK1—central nervous system—multiple sclerosis	0.000951	0.00757	CbGeAlD
Ruxolitinib—BMPR2—brainstem—multiple sclerosis	0.000949	0.00756	CbGeAlD
Ruxolitinib—ROCK1—retina—multiple sclerosis	0.000943	0.00751	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—multiple sclerosis	0.000931	0.00741	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—multiple sclerosis	0.000929	0.00739	CbGeAlD
Ruxolitinib—PLK1—nervous system—multiple sclerosis	0.000929	0.00739	CbGeAlD
Ruxolitinib—MAST1—nervous system—multiple sclerosis	0.000929	0.00739	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—multiple sclerosis	0.000909	0.00724	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—multiple sclerosis	0.000894	0.00712	CbGeAlD
Ruxolitinib—PLK1—central nervous system—multiple sclerosis	0.000894	0.00712	CbGeAlD
Ruxolitinib—MAST1—central nervous system—multiple sclerosis	0.000894	0.00712	CbGeAlD
Ruxolitinib—DCLK3—nervous system—multiple sclerosis	0.00088	0.00701	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—multiple sclerosis	0.000874	0.00696	CbGeAlD
Ruxolitinib—MAST1—cerebellum—multiple sclerosis	0.000874	0.00696	CbGeAlD
Ruxolitinib—Bone pain—Mitoxantrone—multiple sclerosis	0.000867	0.00962	CcSEcCtD
Ruxolitinib—CAMK1—spinal cord—multiple sclerosis	0.00086	0.00685	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—multiple sclerosis	0.00085	0.00677	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—multiple sclerosis	0.000847	0.00675	CbGeAlD
Ruxolitinib—LRRK2—brainstem—multiple sclerosis	0.000842	0.00671	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.000824	0.00915	CcSEcCtD
Ruxolitinib—PLK1—Vidarabine—Cladribine—multiple sclerosis	0.000799	0.193	CbGdCrCtD
Ruxolitinib—PLK1—Adenosine—Cladribine—multiple sclerosis	0.000799	0.193	CbGdCrCtD
Ruxolitinib—JAK1—medulla oblongata—multiple sclerosis	0.000791	0.0063	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—multiple sclerosis	0.000791	0.0063	CbGeAlD
Ruxolitinib—PRKG2—brain—multiple sclerosis	0.000791	0.0063	CbGeAlD
Ruxolitinib—Infection—Fingolimod—multiple sclerosis	0.00079	0.00877	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fingolimod—multiple sclerosis	0.00078	0.00866	CcSEcCtD
Ruxolitinib—PLK3—nervous system—multiple sclerosis	0.000775	0.00617	CbGeAlD
Ruxolitinib—CAMK1D—medulla oblongata—multiple sclerosis	0.000772	0.00615	CbGeAlD
Ruxolitinib—Skin disorder—Fingolimod—multiple sclerosis	0.000772	0.00857	CcSEcCtD
Ruxolitinib—PHKG2—medulla oblongata—multiple sclerosis	0.000768	0.00612	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—multiple sclerosis	0.000755	0.00601	CbGeAlD
Ruxolitinib—GRK1—brain—multiple sclerosis	0.000755	0.00601	CbGeAlD
Ruxolitinib—Pancytopenia—Cladribine—multiple sclerosis	0.000753	0.00836	CcSEcCtD
Ruxolitinib—PLK3—central nervous system—multiple sclerosis	0.000746	0.00594	CbGeAlD
Ruxolitinib—CAMK2G—Azacitidine—Cladribine—multiple sclerosis	0.000745	0.18	CbGdCrCtD
Ruxolitinib—Neutropenia—Cladribine—multiple sclerosis	0.000741	0.00823	CcSEcCtD
Ruxolitinib—PRKCE—brain—multiple sclerosis	0.000739	0.00588	CbGeAlD
Ruxolitinib—MAP3K7—retina—multiple sclerosis	0.000737	0.00587	CbGeAlD
Ruxolitinib—CAMK1—nervous system—multiple sclerosis	0.000725	0.00577	CbGeAlD
Ruxolitinib—TYK2—retina—multiple sclerosis	0.000724	0.00577	CbGeAlD
Ruxolitinib—JAK1—midbrain—multiple sclerosis	0.000723	0.00576	CbGeAlD
Ruxolitinib—DCLK1—midbrain—multiple sclerosis	0.000723	0.00576	CbGeAlD
Ruxolitinib—MKNK2—retina—multiple sclerosis	0.000715	0.00569	CbGeAlD
Ruxolitinib—DAPK3—medulla oblongata—multiple sclerosis	0.00071	0.00565	CbGeAlD
Ruxolitinib—RPS6KA6—brain—multiple sclerosis	0.00071	0.00565	CbGeAlD
Ruxolitinib—PLK1—brain—multiple sclerosis	0.00071	0.00565	CbGeAlD
Ruxolitinib—MAST1—brain—multiple sclerosis	0.00071	0.00565	CbGeAlD
Ruxolitinib—Infestation NOS—Cladribine—multiple sclerosis	0.000707	0.00785	CcSEcCtD
Ruxolitinib—Infestation—Cladribine—multiple sclerosis	0.000707	0.00785	CcSEcCtD
Ruxolitinib—JAK1—spinal cord—multiple sclerosis	0.000706	0.00562	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—multiple sclerosis	0.000706	0.00562	CbGeAlD
Ruxolitinib—MARK2—nervous system—multiple sclerosis	0.000704	0.0056	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—multiple sclerosis	0.000698	0.00556	CbGeAlD
Ruxolitinib—DAPK2—midbrain—multiple sclerosis	0.00069	0.00549	CbGeAlD
Ruxolitinib—Urinary tract infection—Cladribine—multiple sclerosis	0.000687	0.00763	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.000686	0.00762	CcSEcCtD
Ruxolitinib—Fatigue—Fingolimod—multiple sclerosis	0.000685	0.00761	CcSEcCtD
Ruxolitinib—CAMK1—cerebellum—multiple sclerosis	0.000682	0.00543	CbGeAlD
Ruxolitinib—MARK2—central nervous system—multiple sclerosis	0.000678	0.0054	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—multiple sclerosis	0.000673	0.00536	CbGeAlD
Ruxolitinib—DCLK3—brain—multiple sclerosis	0.000673	0.00536	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Cladribine—multiple sclerosis	0.000668	0.00742	CcSEcCtD
Ruxolitinib—Epistaxis—Cladribine—multiple sclerosis	0.000667	0.0074	CcSEcCtD
Ruxolitinib—MARK2—cerebellum—multiple sclerosis	0.000662	0.00527	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—multiple sclerosis	0.000662	0.00527	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—multiple sclerosis	0.000659	0.00525	CbGeAlD
Ruxolitinib—Contusion—Betamethasone—multiple sclerosis	0.000652	0.00723	CcSEcCtD
Ruxolitinib—Contusion—Dexamethasone—multiple sclerosis	0.000652	0.00723	CcSEcCtD
Ruxolitinib—DAPK3—midbrain—multiple sclerosis	0.000649	0.00517	CbGeAlD
Ruxolitinib—Haemoglobin—Cladribine—multiple sclerosis	0.000638	0.00708	CcSEcCtD
Ruxolitinib—Haemorrhage—Cladribine—multiple sclerosis	0.000634	0.00704	CcSEcCtD
Ruxolitinib—DAPK3—spinal cord—multiple sclerosis	0.000633	0.00504	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—multiple sclerosis	0.000613	0.00488	CbGeAlD
Ruxolitinib—Pancytopenia—Azathioprine—multiple sclerosis	0.000612	0.00679	CcSEcCtD
Ruxolitinib—BMPR2—midbrain—multiple sclerosis	0.000605	0.00482	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Mitoxantrone—multiple sclerosis	0.000603	0.00669	CcSEcCtD
Ruxolitinib—TAOK3—brainstem—multiple sclerosis	0.0006	0.00478	CbGeAlD
Ruxolitinib—JAK3—nervous system—multiple sclerosis	0.000598	0.00477	CbGeAlD
Ruxolitinib—JAK1—nervous system—multiple sclerosis	0.000595	0.00474	CbGeAlD
Ruxolitinib—DCLK1—nervous system—multiple sclerosis	0.000595	0.00474	CbGeAlD
Ruxolitinib—CAMK2G—medulla oblongata—multiple sclerosis	0.000592	0.00472	CbGeAlD
Ruxolitinib—PLK3—brain—multiple sclerosis	0.000592	0.00472	CbGeAlD
Ruxolitinib—LRRK2—medulla oblongata—multiple sclerosis	0.000587	0.00468	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—multiple sclerosis	0.00058	0.00462	CbGeAlD
Ruxolitinib—TAOK3—retina—multiple sclerosis	0.000579	0.00461	CbGeAlD
Ruxolitinib—PHKG2—nervous system—multiple sclerosis	0.000577	0.00459	CbGeAlD
Ruxolitinib—JAK3—central nervous system—multiple sclerosis	0.000576	0.00459	CbGeAlD
Ruxolitinib—Infestation—Azathioprine—multiple sclerosis	0.000575	0.00638	CcSEcCtD
Ruxolitinib—Infestation NOS—Azathioprine—multiple sclerosis	0.000575	0.00638	CcSEcCtD
Ruxolitinib—JAK1—central nervous system—multiple sclerosis	0.000572	0.00456	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—multiple sclerosis	0.000572	0.00456	CbGeAlD
Ruxolitinib—LTK—brain—multiple sclerosis	0.000572	0.00456	CbGeAlD
Ruxolitinib—Asthenia—Fingolimod—multiple sclerosis	0.00057	0.00633	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—multiple sclerosis	0.000567	0.0063	CcSEcCtD
Ruxolitinib—JAK3—cerebellum—multiple sclerosis	0.000563	0.00448	CbGeAlD
Ruxolitinib—Pruritus—Fingolimod—multiple sclerosis	0.000563	0.00625	CcSEcCtD
Ruxolitinib—DCLK1—cerebellum—multiple sclerosis	0.00056	0.00446	CbGeAlD
Ruxolitinib—JAK1—cerebellum—multiple sclerosis	0.00056	0.00446	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—multiple sclerosis	0.000559	0.00445	CbGeAlD
Ruxolitinib—STK16—nervous system—multiple sclerosis	0.000558	0.00444	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—multiple sclerosis	0.000555	0.00442	CbGeAlD
Ruxolitinib—HIPK2—nervous system—multiple sclerosis	0.000555	0.00442	CbGeAlD
Ruxolitinib—CAMK1—brain—multiple sclerosis	0.000554	0.00441	CbGeAlD
Ruxolitinib—Malnutrition—Cladribine—multiple sclerosis	0.000552	0.00613	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—multiple sclerosis	0.000549	0.0061	CcSEcCtD
Ruxolitinib—CAMK1D—cerebellum—multiple sclerosis	0.000546	0.00435	CbGeAlD
Ruxolitinib—Flatulence—Cladribine—multiple sclerosis	0.000544	0.00604	CcSEcCtD
Ruxolitinib—MAP3K19—nervous system—multiple sclerosis	0.000544	0.00433	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.000543	0.00603	CcSEcCtD
Ruxolitinib—PHKG2—cerebellum—multiple sclerosis	0.000543	0.00432	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—multiple sclerosis	0.000541	0.00431	CbGeAlD
Ruxolitinib—BMP2K—midbrain—multiple sclerosis	0.000541	0.00431	CbGeAlD
Ruxolitinib—MARK2—brain—multiple sclerosis	0.000538	0.00428	CbGeAlD
Ruxolitinib—STK16—central nervous system—multiple sclerosis	0.000537	0.00428	CbGeAlD
Ruxolitinib—LRRK2—midbrain—multiple sclerosis	0.000537	0.00427	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—multiple sclerosis	0.000534	0.00426	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—multiple sclerosis	0.000534	0.00425	CbGeAlD
Ruxolitinib—DAPK3—nervous system—multiple sclerosis	0.000533	0.00425	CbGeAlD
Ruxolitinib—MAP3K7—medulla oblongata—multiple sclerosis	0.000533	0.00424	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000532	0.0059	CcSEcCtD
Ruxolitinib—CLK2—nervous system—multiple sclerosis	0.000528	0.00421	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—multiple sclerosis	0.000528	0.00421	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—multiple sclerosis	0.000528	0.00421	CbGeAlD
Ruxolitinib—Dizziness—Fingolimod—multiple sclerosis	0.000526	0.00584	CcSEcCtD
Ruxolitinib—STK16—cerebellum—multiple sclerosis	0.000525	0.00418	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—multiple sclerosis	0.000524	0.00417	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—multiple sclerosis	0.000524	0.00417	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Prednisone—multiple sclerosis	0.000523	0.00581	CcSEcCtD
Ruxolitinib—TYK2—medulla oblongata—multiple sclerosis	0.000523	0.00417	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—multiple sclerosis	0.000522	0.00416	CbGeAlD
Ruxolitinib—Haemoglobin—Azathioprine—multiple sclerosis	0.000518	0.00576	CcSEcCtD
Ruxolitinib—MKNK2—medulla oblongata—multiple sclerosis	0.000516	0.00411	CbGeAlD
Ruxolitinib—Haemorrhage—Azathioprine—multiple sclerosis	0.000516	0.00573	CcSEcCtD
Ruxolitinib—DAPK3—central nervous system—multiple sclerosis	0.000513	0.00409	CbGeAlD
Ruxolitinib—ROCK1—nervous system—multiple sclerosis	0.000512	0.00408	CbGeAlD
Ruxolitinib—Anaemia—Cladribine—multiple sclerosis	0.00051	0.00567	CcSEcCtD
Ruxolitinib—CLK2—central nervous system—multiple sclerosis	0.000509	0.00405	CbGeAlD
Ruxolitinib—RET—medulla oblongata—multiple sclerosis	0.000504	0.00401	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—multiple sclerosis	0.000502	0.004	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—multiple sclerosis	0.000499	0.00398	CbGeAlD
Ruxolitinib—Headache—Fingolimod—multiple sclerosis	0.000498	0.00553	CcSEcCtD
Ruxolitinib—TAOK2—brain—multiple sclerosis	0.000498	0.00396	CbGeAlD
Ruxolitinib—BMPR2—nervous system—multiple sclerosis	0.000497	0.00396	CbGeAlD
Ruxolitinib—CLK2—cerebellum—multiple sclerosis	0.000497	0.00396	CbGeAlD
Ruxolitinib—PLK1—Floxuridine—Cladribine—multiple sclerosis	0.000495	0.119	CbGdCrCtD
Ruxolitinib—Pancytopenia—Mitoxantrone—multiple sclerosis	0.000495	0.00549	CcSEcCtD
Ruxolitinib—ROCK1—central nervous system—multiple sclerosis	0.000493	0.00393	CbGeAlD
Ruxolitinib—Neutropenia—Mitoxantrone—multiple sclerosis	0.000487	0.00541	CcSEcCtD
Ruxolitinib—MAP3K7—midbrain—multiple sclerosis	0.000487	0.00388	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—multiple sclerosis	0.000481	0.00383	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—multiple sclerosis	0.000479	0.00381	CbGeAlD
Ruxolitinib—TYK2—midbrain—multiple sclerosis	0.000478	0.00381	CbGeAlD
Ruxolitinib—JAK2—medulla oblongata—multiple sclerosis	0.000476	0.00379	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—multiple sclerosis	0.000475	0.00378	CbGeAlD
Ruxolitinib—Weight increased—Mitoxantrone—multiple sclerosis	0.000474	0.00526	CcSEcCtD
Ruxolitinib—IRAK1—midbrain—multiple sclerosis	0.000472	0.00376	CbGeAlD
Ruxolitinib—MKNK2—midbrain—multiple sclerosis	0.000472	0.00376	CbGeAlD
Ruxolitinib—Weight decreased—Mitoxantrone—multiple sclerosis	0.000471	0.00523	CcSEcCtD
Ruxolitinib—DYRK1A—cerebellum—multiple sclerosis	0.00047	0.00374	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—multiple sclerosis	0.000468	0.00373	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000467	0.00518	CcSEcCtD
Ruxolitinib—TYK2—spinal cord—multiple sclerosis	0.000467	0.00372	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—multiple sclerosis	0.000461	0.00367	CbGeAlD
Ruxolitinib—RET—midbrain—multiple sclerosis	0.00046	0.00367	CbGeAlD
Ruxolitinib—MAP3K3—medulla oblongata—multiple sclerosis	0.000459	0.00365	CbGeAlD
Ruxolitinib—JAK3—brain—multiple sclerosis	0.000457	0.00364	CbGeAlD
Ruxolitinib—JAK1—brain—multiple sclerosis	0.000454	0.00362	CbGeAlD
Ruxolitinib—DCLK1—brain—multiple sclerosis	0.000454	0.00362	CbGeAlD
Ruxolitinib—PLK4—brain—multiple sclerosis	0.000452	0.0036	CbGeAlD
Ruxolitinib—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.000452	0.00501	CcSEcCtD
Ruxolitinib—RET—spinal cord—multiple sclerosis	0.000449	0.00358	CbGeAlD
Ruxolitinib—Infection—Cladribine—multiple sclerosis	0.000448	0.00497	CcSEcCtD
Ruxolitinib—NUAK2—cerebellum—multiple sclerosis	0.000447	0.00356	CbGeAlD
Ruxolitinib—BMP2K—nervous system—multiple sclerosis	0.000445	0.00354	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—multiple sclerosis	0.000445	0.00354	CbGeAlD
Ruxolitinib—CAMK1D—brain—multiple sclerosis	0.000444	0.00353	CbGeAlD
Ruxolitinib—Haematuria—Mitoxantrone—multiple sclerosis	0.000443	0.00492	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cladribine—multiple sclerosis	0.000442	0.00491	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cladribine—multiple sclerosis	0.000441	0.0049	CcSEcCtD
Ruxolitinib—LRRK2—nervous system—multiple sclerosis	0.000441	0.00351	CbGeAlD
Ruxolitinib—PHKG2—brain—multiple sclerosis	0.000441	0.00351	CbGeAlD
Ruxolitinib—Skin disorder—Cladribine—multiple sclerosis	0.000438	0.00486	CcSEcCtD
Ruxolitinib—DAPK2—brain—multiple sclerosis	0.000434	0.00345	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—multiple sclerosis	0.000429	0.00341	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—multiple sclerosis	0.000429	0.00341	CbGeAlD
Ruxolitinib—STK16—brain—multiple sclerosis	0.000427	0.0034	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—multiple sclerosis	0.000425	0.00338	CbGeAlD
Ruxolitinib—JAK2—spinal cord—multiple sclerosis	0.000425	0.00338	CbGeAlD
Ruxolitinib—HIPK2—brain—multiple sclerosis	0.000424	0.00338	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—multiple sclerosis	0.000419	0.00334	CbGeAlD
Ruxolitinib—Haemoglobin—Mitoxantrone—multiple sclerosis	0.000419	0.00465	CcSEcCtD
Ruxolitinib—CAMK2G—cerebellum—multiple sclerosis	0.000419	0.00334	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—multiple sclerosis	0.000419	0.00334	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—multiple sclerosis	0.000418	0.00333	CbGeAlD
Ruxolitinib—Haemorrhage—Mitoxantrone—multiple sclerosis	0.000417	0.00463	CcSEcCtD
Ruxolitinib—MAP3K19—brain—multiple sclerosis	0.000416	0.00331	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—multiple sclerosis	0.000415	0.00331	CbGeAlD
Ruxolitinib—Anaemia—Azathioprine—multiple sclerosis	0.000415	0.00461	CcSEcCtD
Ruxolitinib—MAP3K3—spinal cord—multiple sclerosis	0.000409	0.00326	CbGeAlD
Ruxolitinib—DAPK3—brain—multiple sclerosis	0.000408	0.00325	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—multiple sclerosis	0.000404	0.00322	CbGeAlD
Ruxolitinib—CLK2—brain—multiple sclerosis	0.000404	0.00322	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.0004	0.00444	CcSEcCtD
Ruxolitinib—TYK2—nervous system—multiple sclerosis	0.000393	0.00313	CbGeAlD
Ruxolitinib—ROCK1—brain—multiple sclerosis	0.000391	0.00312	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—multiple sclerosis	0.000389	0.0031	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000389	0.00432	CcSEcCtD
Ruxolitinib—Weight increased—Prednisolone—multiple sclerosis	0.000389	0.00432	CcSEcCtD
Ruxolitinib—Fatigue—Cladribine—multiple sclerosis	0.000389	0.00431	CcSEcCtD
Ruxolitinib—MKNK2—nervous system—multiple sclerosis	0.000388	0.00309	CbGeAlD
Ruxolitinib—TAOK3—midbrain—multiple sclerosis	0.000382	0.00304	CbGeAlD
Ruxolitinib—DYRK1A—brain—multiple sclerosis	0.000382	0.00304	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—multiple sclerosis	0.00038	0.00303	CbGeAlD
Ruxolitinib—BMPR2—brain—multiple sclerosis	0.00038	0.00303	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00038	0.00422	CcSEcCtD
Ruxolitinib—TYK2—central nervous system—multiple sclerosis	0.000379	0.00301	CbGeAlD
Ruxolitinib—RET—nervous system—multiple sclerosis	0.000378	0.00301	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—multiple sclerosis	0.000377	0.003	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—multiple sclerosis	0.000374	0.00298	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—multiple sclerosis	0.000373	0.00297	CbGeAlD
Ruxolitinib—TYK2—cerebellum—multiple sclerosis	0.00037	0.00295	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—multiple sclerosis	0.000365	0.00291	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—multiple sclerosis	0.000365	0.00291	CbGeAlD
Ruxolitinib—RET—central nervous system—multiple sclerosis	0.000364	0.0029	CbGeAlD
Ruxolitinib—Infection—Azathioprine—multiple sclerosis	0.000364	0.00404	CcSEcCtD
Ruxolitinib—NUAK2—brain—multiple sclerosis	0.000363	0.00289	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—multiple sclerosis	0.000359	0.00399	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000359	0.00398	CcSEcCtD
Ruxolitinib—Weight increased—Triamcinolone—multiple sclerosis	0.000358	0.00397	CcSEcCtD
Ruxolitinib—JAK2—nervous system—multiple sclerosis	0.000358	0.00285	CbGeAlD
Ruxolitinib—Weight increased—Methylprednisolone—multiple sclerosis	0.000357	0.00396	CcSEcCtD
Ruxolitinib—Body temperature increased—Cladribine—multiple sclerosis	0.000356	0.00396	CcSEcCtD
Ruxolitinib—RET—cerebellum—multiple sclerosis	0.000356	0.00284	CbGeAlD
Ruxolitinib—Skin disorder—Azathioprine—multiple sclerosis	0.000356	0.00395	CcSEcCtD
Ruxolitinib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00035	0.00388	CcSEcCtD
Ruxolitinib—Infestation—Methylprednisolone—multiple sclerosis	0.00035	0.00388	CcSEcCtD
Ruxolitinib—PLK1—Clofarabine—Cladribine—multiple sclerosis	0.000347	0.0835	CbGdCrCtD
Ruxolitinib—MAP3K3—nervous system—multiple sclerosis	0.000345	0.00275	CbGeAlD
Ruxolitinib—JAK2—central nervous system—multiple sclerosis	0.000344	0.00274	CbGeAlD
Ruxolitinib—Haemoglobin—Prednisolone—multiple sclerosis	0.000344	0.00382	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisolone—multiple sclerosis	0.000342	0.0038	CcSEcCtD
Ruxolitinib—CAMK2G—brain—multiple sclerosis	0.00034	0.00271	CbGeAlD
Ruxolitinib—BMP2K—brain—multiple sclerosis	0.00034	0.00271	CbGeAlD
Ruxolitinib—LRRK2—brain—multiple sclerosis	0.000337	0.00269	CbGeAlD
Ruxolitinib—JAK2—cerebellum—multiple sclerosis	0.000337	0.00268	CbGeAlD
Ruxolitinib—Anaemia—Mitoxantrone—multiple sclerosis	0.000336	0.00372	CcSEcCtD
Ruxolitinib—MAP3K3—central nervous system—multiple sclerosis	0.000332	0.00264	CbGeAlD
Ruxolitinib—Epistaxis—Triamcinolone—multiple sclerosis	0.000331	0.00367	CcSEcCtD
Ruxolitinib—Weight increased—Dexamethasone—multiple sclerosis	0.000325	0.0036	CcSEcCtD
Ruxolitinib—Weight increased—Betamethasone—multiple sclerosis	0.000325	0.0036	CcSEcCtD
Ruxolitinib—MAP3K3—cerebellum—multiple sclerosis	0.000324	0.00258	CbGeAlD
Ruxolitinib—Asthenia—Cladribine—multiple sclerosis	0.000323	0.00359	CcSEcCtD
Ruxolitinib—Weight decreased—Dexamethasone—multiple sclerosis	0.000323	0.00358	CcSEcCtD
Ruxolitinib—Weight decreased—Betamethasone—multiple sclerosis	0.000323	0.00358	CcSEcCtD
Ruxolitinib—Pruritus—Cladribine—multiple sclerosis	0.000319	0.00354	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000317	0.00352	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000316	0.00351	CcSEcCtD
Ruxolitinib—Haemoglobin—Triamcinolone—multiple sclerosis	0.000316	0.00351	CcSEcCtD
Ruxolitinib—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000315	0.0035	CcSEcCtD
Ruxolitinib—Haemorrhage—Triamcinolone—multiple sclerosis	0.000315	0.00349	CcSEcCtD
Ruxolitinib—TAOK3—nervous system—multiple sclerosis	0.000314	0.0025	CbGeAlD
Ruxolitinib—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000314	0.00349	CcSEcCtD
Ruxolitinib—MAP3K2—brain—multiple sclerosis	0.000309	0.00246	CbGeAlD
Ruxolitinib—MAP3K7—brain—multiple sclerosis	0.000306	0.00244	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—multiple sclerosis	0.000303	0.00241	CbGeAlD
Ruxolitinib—TYK2—brain—multiple sclerosis	0.000301	0.00239	CbGeAlD
Ruxolitinib—Dizziness—Cladribine—multiple sclerosis	0.000298	0.00331	CcSEcCtD
Ruxolitinib—IRAK1—brain—multiple sclerosis	0.000297	0.00236	CbGeAlD
Ruxolitinib—MKNK2—brain—multiple sclerosis	0.000297	0.00236	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—multiple sclerosis	0.000296	0.00236	CbGeAlD
Ruxolitinib—Infection—Mitoxantrone—multiple sclerosis	0.000294	0.00327	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—multiple sclerosis	0.00029	0.00322	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.00029	0.00322	CcSEcCtD
Ruxolitinib—Body temperature increased—Azathioprine—multiple sclerosis	0.00029	0.00322	CcSEcCtD
Ruxolitinib—RET—brain—multiple sclerosis	0.000289	0.0023	CbGeAlD
Ruxolitinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000288	0.00319	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—multiple sclerosis	0.000287	0.00319	CcSEcCtD
Ruxolitinib—Haemoglobin—Betamethasone—multiple sclerosis	0.000287	0.00319	CcSEcCtD
Ruxolitinib—Haemorrhage—Dexamethasone—multiple sclerosis	0.000285	0.00317	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—multiple sclerosis	0.000285	0.00317	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—multiple sclerosis	0.000283	0.00314	CcSEcCtD
Ruxolitinib—Headache—Cladribine—multiple sclerosis	0.000282	0.00313	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—multiple sclerosis	0.000281	0.00312	CcSEcCtD
Ruxolitinib—JAK2—brain—multiple sclerosis	0.000273	0.00218	CbGeAlD
Ruxolitinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000273	0.00303	CcSEcCtD
Ruxolitinib—MAP3K3—brain—multiple sclerosis	0.000264	0.0021	CbGeAlD
Ruxolitinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000255	0.00284	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—multiple sclerosis	0.00025	0.00277	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—multiple sclerosis	0.000249	0.00276	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—multiple sclerosis	0.000247	0.00274	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—multiple sclerosis	0.000243	0.00269	CcSEcCtD
Ruxolitinib—Dizziness—Azathioprine—multiple sclerosis	0.000242	0.00269	CcSEcCtD
Ruxolitinib—TAOK3—brain—multiple sclerosis	0.00024	0.00191	CbGeAlD
Ruxolitinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000234	0.0026	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000231	0.00257	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—multiple sclerosis	0.000231	0.00257	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000231	0.00257	CcSEcCtD
Ruxolitinib—Headache—Azathioprine—multiple sclerosis	0.00023	0.00255	CcSEcCtD
Ruxolitinib—Infection—Triamcinolone—multiple sclerosis	0.000222	0.00247	CcSEcCtD
Ruxolitinib—Infection—Methylprednisolone—multiple sclerosis	0.000222	0.00246	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—multiple sclerosis	0.000221	0.00245	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000219	0.00243	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000219	0.00243	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—multiple sclerosis	0.000218	0.00242	CcSEcCtD
Ruxolitinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000217	0.00241	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—multiple sclerosis	0.000216	0.0024	CcSEcCtD
Ruxolitinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000213	0.00236	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—multiple sclerosis	0.000209	0.00232	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—multiple sclerosis	0.000208	0.00231	CcSEcCtD
Ruxolitinib—Infection—Betamethasone—multiple sclerosis	0.000201	0.00224	CcSEcCtD
Ruxolitinib—Infection—Dexamethasone—multiple sclerosis	0.000201	0.00224	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—multiple sclerosis	0.0002	0.00222	CcSEcCtD
Ruxolitinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000199	0.00221	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000199	0.00221	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000199	0.0022	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000199	0.0022	CcSEcCtD
Ruxolitinib—Fatigue—Triamcinolone—multiple sclerosis	0.000193	0.00214	CcSEcCtD
Ruxolitinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000192	0.00213	CcSEcCtD
Ruxolitinib—Headache—Mitoxantrone—multiple sclerosis	0.000186	0.00206	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000183	0.00203	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—multiple sclerosis	0.000181	0.00201	CcSEcCtD
Ruxolitinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000177	0.00196	CcSEcCtD
Ruxolitinib—Infection—Prednisone—multiple sclerosis	0.000175	0.00195	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000175	0.00194	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000175	0.00194	CcSEcCtD
Ruxolitinib—Fatigue—Betamethasone—multiple sclerosis	0.000175	0.00194	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—multiple sclerosis	0.000175	0.00194	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000173	0.00192	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—multiple sclerosis	0.000172	0.0019	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—multiple sclerosis	0.000167	0.00186	CcSEcCtD
Ruxolitinib—Dizziness—Prednisolone—multiple sclerosis	0.000161	0.00178	CcSEcCtD
Ruxolitinib—Asthenia—Triamcinolone—multiple sclerosis	0.00016	0.00178	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—multiple sclerosis	0.00016	0.00178	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—multiple sclerosis	0.00016	0.00178	CcSEcCtD
Ruxolitinib—Asthenia—Methylprednisolone—multiple sclerosis	0.00016	0.00178	CcSEcCtD
Ruxolitinib—Pruritus—Triamcinolone—multiple sclerosis	0.000158	0.00176	CcSEcCtD
Ruxolitinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000158	0.00175	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000153	0.0017	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—multiple sclerosis	0.000152	0.00169	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—multiple sclerosis	0.000152	0.00169	CcSEcCtD
Ruxolitinib—Dizziness—Triamcinolone—multiple sclerosis	0.000148	0.00164	CcSEcCtD
Ruxolitinib—Dizziness—Methylprednisolone—multiple sclerosis	0.000147	0.00164	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—multiple sclerosis	0.000147	0.00163	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—multiple sclerosis	0.000146	0.00162	CcSEcCtD
Ruxolitinib—Asthenia—Betamethasone—multiple sclerosis	0.000146	0.00162	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000145	0.00161	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000145	0.0016	CcSEcCtD
Ruxolitinib—Pruritus—Dexamethasone—multiple sclerosis	0.000143	0.00159	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—multiple sclerosis	0.000143	0.00159	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—multiple sclerosis	0.000143	0.00159	CcSEcCtD
Ruxolitinib—Headache—Triamcinolone—multiple sclerosis	0.00014	0.00155	CcSEcCtD
Ruxolitinib—Headache—Methylprednisolone—multiple sclerosis	0.00014	0.00155	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—multiple sclerosis	0.00014	0.00155	CcSEcCtD
Ruxolitinib—Dizziness—Betamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Ruxolitinib—Dizziness—Dexamethasone—multiple sclerosis	0.000134	0.00149	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Ruxolitinib—Headache—Betamethasone—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—multiple sclerosis	0.000127	0.00141	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—multiple sclerosis	0.000125	0.00139	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—multiple sclerosis	0.000117	0.0013	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—multiple sclerosis	0.000117	0.0013	CcSEcCtD
Ruxolitinib—Headache—Prednisone—multiple sclerosis	0.000111	0.00123	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—multiple sclerosis	0.000106	0.00118	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—multiple sclerosis	0.000104	0.00116	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—multiple sclerosis	9.76e-05	0.00108	CcSEcCtD
Ruxolitinib—CYP3A4—nervous system—multiple sclerosis	9.55e-05	0.00076	CbGeAlD
Ruxolitinib—Headache—Methotrexate—multiple sclerosis	9.25e-05	0.00103	CcSEcCtD
Ruxolitinib—CYP3A4—central nervous system—multiple sclerosis	9.19e-05	0.000732	CbGeAlD
Ruxolitinib—CYP3A4—Metabolism—SRM—multiple sclerosis	5.45e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—STAT3—multiple sclerosis	5.41e-06	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTGER4—multiple sclerosis	5.4e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL10—multiple sclerosis	5.39e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—multiple sclerosis	5.37e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD80—multiple sclerosis	5.32e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—multiple sclerosis	5.31e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PGR—multiple sclerosis	5.31e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—multiple sclerosis	5.31e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—POMC—multiple sclerosis	5.31e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—multiple sclerosis	5.27e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD86—multiple sclerosis	5.26e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—multiple sclerosis	5.25e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—multiple sclerosis	5.24e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—multiple sclerosis	5.24e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—multiple sclerosis	5.23e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2—multiple sclerosis	5.22e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MAPK1—multiple sclerosis	5.21e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCR3—multiple sclerosis	5.21e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCL2—multiple sclerosis	5.19e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MYC—multiple sclerosis	5.19e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—TGFB1—multiple sclerosis	5.18e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—multiple sclerosis	5.17e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD28—multiple sclerosis	5.16e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—STAT3—multiple sclerosis	5.1e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—MAPK1—multiple sclerosis	5.08e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MAPK1—multiple sclerosis	5.08e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR2—multiple sclerosis	5.07e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD80—multiple sclerosis	5.06e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MAPK1—multiple sclerosis	5.06e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.05e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MAPK1—multiple sclerosis	5.04e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CD86—multiple sclerosis	5.01e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2RA—multiple sclerosis	4.98e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—multiple sclerosis	4.95e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL5—multiple sclerosis	4.93e-06	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-A—multiple sclerosis	4.92e-06	2.28e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MAPK1—multiple sclerosis	4.92e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MAPK1—multiple sclerosis	4.91e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CD86—multiple sclerosis	4.86e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CD80—multiple sclerosis	4.8e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL5—multiple sclerosis	4.79e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—STAT3—multiple sclerosis	4.78e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TYK2—multiple sclerosis	4.77e-06	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—POMC—multiple sclerosis	4.76e-06	2.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CD80—multiple sclerosis	4.72e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CD86—multiple sclerosis	4.71e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TYK2—multiple sclerosis	4.71e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CNR1—multiple sclerosis	4.68e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—multiple sclerosis	4.68e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CCR5—multiple sclerosis	4.67e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—multiple sclerosis	4.65e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—multiple sclerosis	4.65e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL5—multiple sclerosis	4.64e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MAPK1—multiple sclerosis	4.64e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—multiple sclerosis	4.62e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SPP1—multiple sclerosis	4.56e-06	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—POMC—multiple sclerosis	4.56e-06	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HLA-A—multiple sclerosis	4.55e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TLR4—multiple sclerosis	4.5e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DRB1—multiple sclerosis	4.5e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TYK2—multiple sclerosis	4.49e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—POMC—multiple sclerosis	4.49e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—multiple sclerosis	4.47e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL2—multiple sclerosis	4.47e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCR5—multiple sclerosis	4.44e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SPP1—multiple sclerosis	4.43e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TGFB1—multiple sclerosis	4.43e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—multiple sclerosis	4.4e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—multiple sclerosis	4.4e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL2—multiple sclerosis	4.39e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—STAT3—multiple sclerosis	4.39e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2RA—multiple sclerosis	4.38e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—MAPK1—multiple sclerosis	4.37e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TGFB1—multiple sclerosis	4.34e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MAPK1—multiple sclerosis	4.34e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—multiple sclerosis	4.34e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—POMC—multiple sclerosis	4.32e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ICAM1—multiple sclerosis	4.32e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—multiple sclerosis	4.31e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCR5—multiple sclerosis	4.31e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SPP1—multiple sclerosis	4.3e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—MAPK1—multiple sclerosis	4.3e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—MAPK1—multiple sclerosis	4.26e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2RA—multiple sclerosis	4.25e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—multiple sclerosis	4.24e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL2—multiple sclerosis	4.23e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—multiple sclerosis	4.22e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—multiple sclerosis	4.22e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL10—multiple sclerosis	4.21e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—multiple sclerosis	4.21e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—multiple sclerosis	4.2e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—multiple sclerosis	4.19e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCR5—multiple sclerosis	4.18e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD80—multiple sclerosis	4.16e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—multiple sclerosis	4.13e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2RA—multiple sclerosis	4.12e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—multiple sclerosis	4.06e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TYK2—multiple sclerosis	4.05e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—multiple sclerosis	4.05e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—multiple sclerosis	4.04e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—multiple sclerosis	4e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MAPK1—multiple sclerosis	3.99e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TYK2—multiple sclerosis	3.99e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—multiple sclerosis	3.98e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—multiple sclerosis	3.97e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—multiple sclerosis	3.92e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—multiple sclerosis	3.92e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—multiple sclerosis	3.91e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—multiple sclerosis	3.9e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—multiple sclerosis	3.9e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—multiple sclerosis	3.89e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—multiple sclerosis	3.87e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—multiple sclerosis	3.87e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—multiple sclerosis	3.87e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—multiple sclerosis	3.85e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—TYK2—multiple sclerosis	3.84e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD80—multiple sclerosis	3.84e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.84e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.84e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MAPK1—multiple sclerosis	3.83e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—multiple sclerosis	3.8e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—multiple sclerosis	3.78e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—multiple sclerosis	3.77e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—multiple sclerosis	3.77e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—multiple sclerosis	3.76e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—multiple sclerosis	3.75e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—multiple sclerosis	3.74e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—multiple sclerosis	3.71e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MAPK1—multiple sclerosis	3.69e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD86—multiple sclerosis	3.68e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CD80—multiple sclerosis	3.65e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—multiple sclerosis	3.63e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL5—multiple sclerosis	3.63e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—multiple sclerosis	3.62e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—multiple sclerosis	3.57e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK1—multiple sclerosis	3.55e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CD80—multiple sclerosis	3.55e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—multiple sclerosis	3.52e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.51e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TYK2—multiple sclerosis	3.51e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—multiple sclerosis	3.47e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CD80—multiple sclerosis	3.44e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—multiple sclerosis	3.4e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—multiple sclerosis	3.37e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—multiple sclerosis	3.37e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPP1—multiple sclerosis	3.36e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—multiple sclerosis	3.36e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—multiple sclerosis	3.34e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—multiple sclerosis	3.34e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—multiple sclerosis	3.32e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—multiple sclerosis	3.3e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—multiple sclerosis	3.3e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—multiple sclerosis	3.3e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—multiple sclerosis	3.29e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—multiple sclerosis	3.27e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR5—multiple sclerosis	3.27e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—multiple sclerosis	3.24e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TYK2—multiple sclerosis	3.24e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK1—multiple sclerosis	3.23e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2RA—multiple sclerosis	3.22e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—multiple sclerosis	3.2e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—multiple sclerosis	3.2e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—multiple sclerosis	3.19e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—multiple sclerosis	3.17e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—multiple sclerosis	3.14e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—multiple sclerosis	3.14e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TYK2—multiple sclerosis	3.08e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—multiple sclerosis	3.07e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—multiple sclerosis	3.07e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—multiple sclerosis	3.06e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—multiple sclerosis	3.04e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—multiple sclerosis	3e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—multiple sclerosis	2.99e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—multiple sclerosis	2.97e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—multiple sclerosis	2.95e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—multiple sclerosis	2.95e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—multiple sclerosis	2.93e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—multiple sclerosis	2.93e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—multiple sclerosis	2.92e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.91e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TYK2—multiple sclerosis	2.9e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—multiple sclerosis	2.86e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—multiple sclerosis	2.84e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—multiple sclerosis	2.83e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—multiple sclerosis	2.79e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—multiple sclerosis	2.78e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—multiple sclerosis	2.77e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—multiple sclerosis	2.73e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—multiple sclerosis	2.72e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD80—multiple sclerosis	2.69e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—multiple sclerosis	2.64e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—multiple sclerosis	2.63e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—multiple sclerosis	2.59e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—multiple sclerosis	2.59e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—multiple sclerosis	2.58e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	2.57e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—multiple sclerosis	2.55e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—multiple sclerosis	2.54e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—multiple sclerosis	2.5e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—multiple sclerosis	2.49e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—multiple sclerosis	2.48e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—multiple sclerosis	2.46e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—multiple sclerosis	2.44e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	2.43e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—multiple sclerosis	2.42e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—multiple sclerosis	2.36e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—multiple sclerosis	2.33e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—multiple sclerosis	2.31e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—multiple sclerosis	2.29e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TYK2—multiple sclerosis	2.27e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—multiple sclerosis	2.27e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—multiple sclerosis	2.26e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—multiple sclerosis	2.23e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—multiple sclerosis	2.2e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	2.16e-06	9.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—multiple sclerosis	2.11e-06	9.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—multiple sclerosis	2.1e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—multiple sclerosis	2.1e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—multiple sclerosis	2.09e-06	9.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—multiple sclerosis	2.06e-06	9.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—multiple sclerosis	2.03e-06	9.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	2.01e-06	9.27e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	2e-06	9.25e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—multiple sclerosis	1.98e-06	9.16e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	1.96e-06	9.07e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—multiple sclerosis	1.95e-06	9.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—multiple sclerosis	1.95e-06	9e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—multiple sclerosis	1.94e-06	8.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—multiple sclerosis	1.91e-06	8.8e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—multiple sclerosis	1.89e-06	8.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—multiple sclerosis	1.89e-06	8.72e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—multiple sclerosis	1.88e-06	8.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—multiple sclerosis	1.88e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—multiple sclerosis	1.85e-06	8.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—multiple sclerosis	1.79e-06	8.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—multiple sclerosis	1.72e-06	7.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.67e-06	7.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—multiple sclerosis	1.59e-06	7.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—multiple sclerosis	1.58e-06	7.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	1.51e-06	6.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—multiple sclerosis	1.48e-06	6.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—multiple sclerosis	1.47e-06	6.8e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—multiple sclerosis	1.46e-06	6.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—multiple sclerosis	1.44e-06	6.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—multiple sclerosis	1.42e-06	6.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—multiple sclerosis	1.11e-06	5.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—multiple sclerosis	1e-06	4.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—multiple sclerosis	8.63e-07	3.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—multiple sclerosis	7.87e-07	3.64e-06	CbGpPWpGaD
